Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The expanding role of prophylaxis with recombinant activated factor VII.

Authors: Massimo Franchini; Franco Manzato; Gian Luca Salvagno; Martina Montagnana; Marco Zaffanello; Giuseppe Lippi
Journal: Semin Thromb Hemost Date: 2010-02-18 Impact factor: 4.180

6. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.

Authors: W K Hoots; L S Ebbesen; B A Konkle; G K-H Auerswald; H R Roberts; J Weatherall; J-M Ferran; R C R Ljung
Journal: Haemophilia Date: 2008-02-12 Impact factor: 4.287

7. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.

Authors: B A Konkle; L S Ebbesen; E Erhardtsen; R P Bianco; T Lissitchkov; L Rusen; M A Serban
Journal: J Thromb Haemost Date: 2007-09 Impact factor: 5.824

8. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Authors: M Morfini; G Auerswald; R A Kobelt; G F Rivolta; J Rodriguez-Martorell; F A Scaraggi; C Altisent; J Blatny; A Borel-Derlon; V Rossi
Journal: Haemophilia Date: 2007-09 Impact factor: 4.287

The expanding role of prophylaxis with recombinant activated factor VII.

Review 1. Clinical use of recombinant FVIIa (rFVIIa).

2. Mechanism of action of recombinant factor VIIa.

Review 3. Recombinant factor VIIa. An update on its clinical use.

Review 4. Prophylaxis in haemophilia patients with inhibitors.

Review 5. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.

6. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.

7. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.

8. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

9. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?

10. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.

Review 1. Recombinant activated factor VII in clinical practice: a 2014 update.